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A b s t r a c t  
The present study was aimed to formulate and evaluate oral mucoadhesive drug delivery system of 
purified Hibiscus esculentus L polysaccharide (HEP) using famotidine as model drug.  
A central composite design for 2 factors at 3 levels each was employed to evaluate the effect of 
critical variables i.e. concentration of HEP and PVP K30 on drug release and mucoadhesive 
properties of the formulated tablets. FT-IR spectroscopy and Differential Scanning Calorimetry was 
carried out to evaluate drug polymer interaction. Formulated tablets were evaluated for physical 
properties, drug release characteristic and physical stability. Ex-vivo mucoadhesion study using goat 
gastric mucosa was carried out to ascertain the mucoadhesion potential of formulated tablets. 
The response surface analysis clearly indicated the dominating effect of HEP on mucoadhesive 
strength, mucoadhesion time and dissolution half life, while PVP K30 has an additive effect on all 
afore mentioned responses. The drug release from the matrix tablets was highly affected by the 
concentration of release retardants polysaccharide. The kinetics of drug release was found to be 
first order in low concentration but with increase in polymer concentration the release pattern shifted 
towards zero order and is governed by both Higuchi and Hixson-Crowel equation indicating a 
coupling effect of diffusion and erosion.  
The result of the study suggests that, HEP can be optimistically explored as excellent mucoadhesive 
agent with controlled release characteristics. 
Keywords: Hibiscus esculentus polysaccharide, Mucoadhesive drug delivery system, Mucoadhesive 
strength, central composite design (CCD), Texture analysis. 
 
Introduction 
The real challenge in the development of an oral controlled-release 
drug delivery system is not just to sustain the drug release but also 
to prolong the presence of the dosage form within the 
gastrointestinal tract (GIT) until all the drug is completely released 
at the desired period of time. In recent years gastro-retentive drug 
delivery systems has received enormous attention by the 
formulators especially for the drugs with limited absorption window. 
Several gastro-retentive drug delivery approaches being designed 
and developed, including high density or sinking systems that is 
retained in the bottom of the stomach [1], low density or floating 
systems that causes buoyancy in gastric fluid [2], mucoadhesive 
systems that causes bioadhesion to stomach mucosa [3], 
unfoldable, extendible, or swellable systems which limits emptying 
of the dosage forms through the pyloric sphincter of stomach [4], 
super-porous hydrogel systems [5], magnetic systems [6] etc. The 
advantages associated with the mucoadhesive drug delivery 
systems include increased dosage form residence time, improved 
drug bioavailability, reduced administration frequency and 
simplified administration of a dosage formand termination of a 
therapy as well as the possibility of targeting particular body sites 
and tissues [7]. Excellent mucoadhesive performance is typically 
observed for polymers possessing charged groups or non-ionic 
functional groups capable of forming hydrogen bonds with mucosal 
surfaces [7]. 
Optimization with factorial designs is a powerful, efficient and 
systemic tool that shortens the time required for the development 
of pharmaceutical dosage forms and improves research and 
development work [8, 9]. The response surface method has been 
applied to dosage form design for various kinds of drugs by many 
researchers [10]. In the development of an extended release 
dosage form an important issue is to design an optimized 
formulation with minimum number of trials in short time. For this a 
computerized optimization technique, based on response surface 
methodology (RSM) utilizing a polynomial equation has been 
widely used. RSM can be defines as a statistical method that uses 
quantitative data from appropriate experiments to determine and 
simultaneously solve multivariate equations [11]. Many statistical 
experimental designs have been recognized as useful techniques 
to optimize process variables. RSM is widely used when only a few 
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significant factors are involved in optimization. Various types of 
RSM designs include 32 full factorial designs [12, 13], Central 
Composite Design [14] and Box-Behnken design [15]. 
Famotidine is histamine H2 receptor antagonist. It is widely 
prescribed in active duodenal ulcers, gastric ulcers, gastro 
esophageal reflux disease and erosive esophagitis [16]. 
Famotidine is having ashort biological half-life of 2.5 - 3.5 hrs and 
40 ă45% oral bioavailability [17]. Since the drug is sparingly soluble 
in water (0.1%at 20ÀC), has a short elimination half-life and narrow 
absorption window in proximal GI tract, several attempts have been 
made to improve its physiological availability [18]. 
Material and Methods 
Materials 
Famotidine was obtained as a gift sample from Torrent 
Pharmaceutical Limited., Indrad, India. Hibiscus esculentus fruits 
were purchased from local market of Guwahati, Assam, India and 
the polysaccharide was extracted and purified in laboratory as per 
the method describe by Dash S. et al [19]. Polyvinyl Pyrrolidine K-
30 (PVP K-30) was obtained from S.D Fine Chemicals Ltd., 
Mumbai, India. All other chemicals and reagents used were of 
analytical grade. 
Drug-polysaccharide compatibility by FTIR and DSC 
study 
The study of drugăexcipient compatibility is an important process in 
the development of a stable solid dosage form [20]. Incompatibility 
between drugs and polymers can alter the stability and 
bioavailability of drugs, thereby affecting its safety and/or efficacy.  
FTIR spectra of famotidine, HEP and 1:1 w/w physical mixture of 
famotidine-HEP, stored 24hours in a glass dessicator, were 
recorded after on a FTIR spectrophotometer (Bruker Alpha-E, 
Bruker®, Germany) in the range of 400–4000 cmî1 using an ATR 
attachment equipped with zinc selenium optical assembly. The 
spectrum was a mean of sixteen consecutive scans of the same 
sample. Processing of the FTIR data was performed using OPUS 
software. 
A differential scanning calorimeter (DSC-60, Shimadzu, Japan) 
was used for analysis of thermal stress on HEP famotidine and 
their mixture. Individual samples (famotidine and HEP) as well as 
1:1 w/w physical mixtures of drug and excipients were weighed to 
about 5 mg in the DSC aluminum pan and scanned in the 
temperature range of 25–300ÀC in nitrogen environment. A heating 
rate of 20ÀC per minute was used, and the thermograms were 
reviewed for evidence of any interaction. 
Experimental Design 
A 32 full factorial design was constructed where the amounts of HE 
polysaccharide (X1) and PVP K30 (X2) were selected as two 
independent variables. It is suitable for investigating the quadratic 
response and for constructing a second-order polynomial model, 
thus enabling optimization. The levels of two factors were selected 
on the basis of literatures available and preliminary investigations 
carried out before implementing the experimental design. 
Optimization of formulation of mucoadhesive matrix tablet was 
done by Design Expert® Software (Version 8.2.0, Stat-Ease Inc.) 
All the formulations were prepared and evaluated for various pre-
compression & post-compression parameters and effect of the 
polymers was studied on the in-vitro performances. The data 
obtained was interpreted in the software and polynomial equation 
was obtained. The responses (dependent variables) studied for this 
investigation was mucoadhesion time (Y1), dissolution half-life (Y2) 
and release exponent (Y3). The polynomial equations required for 
the purpose of ANOVA are obtained from the Factorial designs. 
The equation is shown as below. Table 1 summarizes the levels of 
independent variables. 
Y= β0 + β1 X1 + β2 X2 + β12 X1X2 + β11 X12 + β22 X22 
⁄⁄⁄⁄⁄⁄⁄.⁄  Eq. 1 
 
Table ă 1: Coded variables with respective levels. 
Factors (Independent 
variable) 
Actual values (% w/w) Response (independent variable) 
 1 0 + 1 
X1 20 30 40 Y1 = Mucoadhesion force 
Y2 = Dissolution half-life 
Y3 = Release exponent X2 5 7.5 10 
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Table ă 2: Composition of formulations for various batches. 
Ingredients 
Weight of Ingredients mg/tablet
MT 1 MT 2 MT 3 MT 4 MT 5 MT 6 MT 7 MT 8 MT 9 
Famotidine 40 40 40 40 40 40 40 40 40 
Hibiscus esculentus 
polysaccharide 32 32 32 48 48 48 64 64 64 
Polyvinyl pyrollidone (PVP 
K30) 
8 12 16 8 12 16 8 12 16 
Microcrystalline cellulose 75.2 71.2 67.2 59.2 55.2 51.2 43.2 39.2 35.2 
Magnesium stearate 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 
Talc 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 
Total Tablet weight 160 160 160 160 160 160 160 160 160 
 
Preparation of Mucoadhesive matrix tablets of 
Famotidine 
 Table ă 2 enlist the composition of different trial formulations 
prepared using Hibiscus esculentus polysaccharide (HEP) as 
mucoadhesive material and polyvinyl pyrrolidone (PVP) K30 as 
binder. Amount of talc and magnesium stearate was kept 
unchanged for all the formulations. Microcrystalline cellulose 
(MCC) was used as diluent. Powdered HEP and MCC was mixed 
with famotidine in a V-blender for 10 mins. The powder blend was 
granulated with PVP K30 solution and screened through a sieve # 
12, wet granules were dried at 50ÀC for 6 hours. Dried granules 
were screened through sieve # 16 and magnesium stearate and 
talc was mixed for 5 minutes in a double-cone blender (VJ 
Instruments Pvt. Ltd. India) for 5mins at 20 rpm. Tablets were 
compressed on a 8-station Mini Press-I rotary tablet compression 
machine (Shakti Pharmatech. India) fitted with 8-mm flat-faced 
round punches using sufficient compression force to obtain a 
hardness of 4 to 5 Kg/cmñ containing 40 mg of famotidine per 
tablet. 
Tablet thickness 
A vernier caliper was used to determine thickness of 10 randomly 
selected tablets. Results are expressed as mean values μ SD. 
Hardness and tensile strength 
Five tablets were randomly selected from each formulation and 
crushing strength of each tablet was measured using Monsanto 
hardness tester. The mean hardness of five tablets was 
determined and expressed in Kg/cm2. 
Friability 
The friability test was carried out in Roche Friabilator [20]. 20 
tablets were randomly selected from each batch and initial weight 
(Wo) was determined after dedusting and placed in the rotating 
drum of friabilator. They were subjected to 100 falls of 6 inches 
height (25rpm for 4min). After completion of 100 rotations, the 
tablets were removed, dedusted by using soft-bristle brush and 
weighed (W1) accurately. The test was repeated for three times. 
The percent loss in weight (or friability) was calculated by the 
formula given below: 
 
% Friability= ቀ1- W1
W0
ቁ ×100 ⁄⁄⁄⁄..⁄⁄⁄. Eq. 2 
Drug content uniformity  
Twenty tablets were weighed and powdered. An amount of the 
powder equivalent to 20mg of famotidine was dissolved in 100ml of 
0.1N hydrochloric acid, followed by stirring for 30 minutes. The 
solution was filtered through a 0.45μ membrane filter, diluted 
suitably and the absorbance of resultant solution was measured 
spectrophotometrically (UV-1800, Shimadzu, Kyoto, Japan) at 
265nm using 0.1 N hydrochloric acid as blank. 
Swelling Index 
The swelling of tablet involves the absorption of a liquid resulting in 
an increase in weight and volume. Liquid uptake by the polymers 
results to saturation of capillary spaces within the polymer chain or 
hydration of macromolecule [23]. To determine the extent of matrix 
swelling, three tablets from each batch were weighed and placed in 
a petri-dish containing 25 ml of 0.1N hydrochloric acid. After each 2 
hrs interval the tablets were removed from media, excess of media 
was wiped off by using filter paper and weighed again up to 12 hrs 
[24]. The swelling index was calculated using following formula. 
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Swelling Index ሺS.I.ሻ= Wt-W0
W0
×100 …………………… Eq. 3 
In vitro drug release study  
In vitro release of famotidine from the prepared mucoadhesive 
tablets was studied using USP XXIV dissolution rate test apparatus 
(DS-8000, Labindia Analytical Instruments Pvt. Ltd., Mumbai, India) 
employing the paddle (Apparatus-II). 900mL of 0.1N hydrochloric 
acid was used as dissolution medium maintained at a temperature 
of 37μ0.5ÀC and the paddle was rotated at 50 rpm. 5mL of samples 
were withdrawn with a syringe fitted with a pre-filter at 
predetermined time intervals and immediately replaced with 5mL of 
fresh medium maintained at 37μ0.5ÀC. The samples were suitably 
diluted and the absorbance was measured at 265nm using UV-
Visible spectrophotometer (UV-1800Shimadzu, Kyoto, Japan). The 
in vitro release study was performed in triplicate for each 
formulation. Cumulative percentage drug release was calculated 
using the equation obtained from the standard curve. 
Drug release kinetic study 
Mathematical modeling of drug delivery and predictability of drug 
release mechanism is a field of steadily increasing industrial 
importance. The accuracy of a mathematical theory generally 
increases with increasing model complexity. There is no general 
mathematical theory that can be applied to all types of drug 
delivery systems. To investigate the kinetics of drug release from 
formulated famotidine mucoadhesive tablets, the data of in-vitro 
drug release study were fitted to different mathematical models. 
The order of drug release from matrix systems was described by 
using zero order [25] or first order kinetics [26, 27]. The mechanism 
of drug release from matrix systems was studied by using Higuchi 
diffusion model [28] and Hixson-Crowell erosion model [29]. 
Korsemeyer-Peppas support the drug release mechanism for 
further judgment [30, 31]. The respective equations for these 
models are shown below: 
 
Zero Order Model : Q0 Ӎ  Qt = K0t ⁄⁄⁄⁄⁄⁄⁄⁄⁄.. Eq. 4 
First Order Model  : logC = 
logC0 Ӎ  Kt
2.303
 ⁄⁄⁄⁄⁄⁄⁄⁄⁄ Eq. 5 
Higuchi Model  :ft = Q = AටD(2C‐CS)CSt ⁄⁄⁄⁄⁄ Eq. 6 
Hixson-Crowell Model :W0
1
3ൗ ‐Wt
1
3ൗ  = ҡt ⁄⁄⁄⁄⁄⁄⁄⁄⁄. Eq. 7 
Korsemeyer ă Peppas Model :Mt M¥ = Kt
n⁄  ⁄⁄⁄⁄⁄⁄ Eq. 8 
Mucoadhesion study 
In vitro/ex vivo tests are important in the development of controlled 
release mucoadhesive drug delivery systems because these tests 
contribute to studies of mechanical and physical stability, 
superficial interaction between formulation and mucous membrane, 
duration of adhesion and strength of the bioadhesive bond. 
Determination of ex-vivo mucoadhesion strength 
Mucoadhesion testing of the sample tablets was carried out using a 
texture analyzer (TAXT plus, Stable Micro Systems, UK) with 50N 
load cell equipped with mucoadhesive holder [32]. A tablet was 
attached to the cylindrical probe (10mm in diameter) by double 
sided adhesive tape. Goat gastric mucosa was utilized as the 
model membrane for mucoadhesive strength determination of 
various formulations. The tissue (about 20X20mm) was 
equilibrated for 15min at 37.0μ0.5ÀC before placing onto the holder 
stage of mucoadhesive holder. The probe with the tablet attached 
was lowered at a rate of 0.5mm/sec. until a contact with the 
membrane was made. A contact force of 1N was maintained for 60 
second, and the probe was subsequently withdrawn at a 
0.5mm/sec. to the distance of 15mm. By using the texture 
analyzer, the maximum force required to separate the tablet from 
the tissue (i.e. maximum detachment force; Fmax) was measured 
using Texture Exponent 32 software. 
Determination of ex-vivo mucoadhesion time 
The ex-vivo mucoadhesive time was determined using a modified 
USP disintegration test apparatus. The goat gastric mucosa was 
collected from local slaughter house and used within 2 hours of 
sacrificing the animal. The mucous membrane was separated by 
removing the underlining fatty layer and loose tissues. 900ml 0.1N 
hydrochloric acid was used as disintegration medium and 
maintained at 37μ2ĈC throughout the experiment [33]. The 
segment of goat gastric mucosa (3×3cm) was glued with 
cyanoacrylate glue to the surface of glass slab, which was then 
vertically attached to the apparatus. Three tablets of each 
formulation were hydrated on one surface with 0.1N hydrochloric 
acid and the hydrated surface was brought into contact with the 
mucosal membrane and allowed the apparatus to move up and 
down. The time required for complete detachment of the tablets 
from surface was recorded. The results were analyzed for mean 
and standard deviation. 
Physical stability study 
Short-term physical stability studies were carried out according to 
the International Conference on Harmonization (ICH) guidelines 
[34]. The optimized formulation of Famotidine mucoadhesive 
tablets (MOpt) were enclosed in a polyethylene bottle using a screw 
cap and placed in a stability test chamber (Remi Environment Test 
Chamber, Remi Laboratory Instruments, India). The chamber 
environmental condition was set at 40ÀC temperature and75% 
relative humidity and maintained for three months. At specified time 
intervals, the tablets were examined for any statistical difference in 
their hardness values, matrix integrity, in-vitro dissolution profile 
mucoadhesion strength and mucoadhesion time using a paired 
StudentÊs t-test [35]. Differences were considered to be significant 
at p < 0.05. 
Statistical Analysis 
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All experiments were repeated at least three times. Results are 
expressed as means μ standard deviation (SD). Statistical analysis 
was carried out employing one-way ANOVA followed by 
studentized range test using the Design Expert® Software (Version 
8.2.0, Stat-Ease Inc.). A p-value less than 0.05 were considered 
statistically significant. 
Result and discussion 
Drug-excipient compatibility study 
To assess the compatibility between HEP and famotidine, the 
spectra of their physical mixture was compared with spectrum of 
individual components (Figure ă 1). The FTIR spectra of HEP 
shows peaks at 3233.69 cm-1 (―OH), 719.23 cm-1 (―CŲO), 
1612.69 cm-1 (―COO―), 1411.18 cm-1 (―COO―), 1243.84 cm-
1 (―C―O). The peaks at 2924.16 cm-1 is characteristic of methyl 
C-H stretching associated with aromatic rings. Peak at 3233.69 cm-
1 is due to hydrogen bonded hydroxyl groups that contribute to the 
complex vibrational stretches. The FTIR spectra of famotidine 
shows mejor peaks at 3505.56 (N―H), 3103.39 (C―H), 1373.17 
(―SO2), 1181.28 (―SO2), 904.37 (S―N). The FTIR spectrum of 
physical mixture shows all characteristic peaks with minor shift 
indicating absence of interactions. This spectrum showed, alcoholic 
ăOH stretch at 3500.93 cmă1, ăNH2 & -NH stretch at 3394 & 
3256.63 cmă1 respectively, C=N stretch at 1597.82 cmă1, C-S 
stretch at 716.18 cmă1, S(=O)2 asymmetric and symmetric 
stretching at 1326.10 cmă1 and 1140.21 cmă1 respectively. All the 
peaks of HEP and famotidine remains unchanged in the physical 
mixture. 
 
 
 
Figure ă 1: FTIR spectra of famotidine, HEP and their physical mixture. 
 
DSC thermograms of famotidine, HEP and their physical mixture is 
shown in figure ă 2. DSC thermogram of famotidine shows a sharp 
endothermic peak at 165.96 ÀC which is characteristic melting peak 
of pure famotidine. DSC thermogram of HEP shows its melting 
endothermic peak at 146.04ÀC. Thermogram of mixture of 
famotidine with HEP showed a wider melting endotherm at 
158.28ÀC due to melting of famotidine and polymer in mixture. The 
onset of the endotherm is 142.17ÀC and ends at 169.04ÀC which 
indicating the overlapping of both melting peaks of famotidine and 
HEP. There was neither any other endothermic peak nor any sharp 
exothermic peaks within the scanning range indicating there is not 
significant chemical and physical interaction between famotidine 
and HEP. 
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Figure ă 2: DSC thermograms of Famotidine, HEP and their physical mixture. 
 
Post-compression tablet evaluation studies 
The assessment results of thickness, hardness, friability and drug 
content are presented in Table 3. The tablet thickness of the 
various formulations was found to be in the range of 2.61 μ 0.042 
to 2.74 μ 0.075. The hardness of all tablet were in the range of 5.1 
μ 0.6 to 5.6 μ 0.6 kg/cm2. Hardness increased as the amount of 
concentration of HEP increased. This indicates the binding 
potentiality of the polysaccharide. Since tablet hardness is not a 
perfect index to evaluate the strength of the tablets, friability 
percentage was also used to test the hardness of tablets. The 
friability values of all the prepared tablets were less than 1% which 
indicated that the test was compiled with the official compendial 
tests for tablets as per IP. 
 
       Table ă 3: Post-compression characteristics of the famotidine mucoadhesive tablets. 
Parameters 
Formulations Batches
MT 1 MT 2 MT 3 MT 4 MT 5 MT 6 MT 7 MT 8 MT 9
Thickness (mm.) a 
2.62 
μ 
0.065 
2.61 
μ 
0.042 
2.62
μ 
0.039 
2.68
μ 
0.071 
2.70
μ 
0.041 
2.66
μ 
0.081 
2.72 
μ 
0.027 
2.74 
μ 
0.075 
2.73
μ 
0.031 
Hardness (Kg/cm2) 
a 
5.1 
μ 
0.6 
5.3 
μ 
0.8 
5.4
μ 
0.3 
5.4
μ 
0.6 
5.4
μ 
0.3 
5.2
μ 
0.4 
5.5 
μ 
0.5 
5.5 
μ 
0.4 
5.6
μ 
0.6 
Friability (% w/w) b 
0.64 
μ 
0.020 
0.66 
μ 
0.016 
0.64
μ 
0.021 
0.43
μ 
0.019 
0.42
μ 
0.011 
0.40
μ 
0.015 
0.34 
μ 
0.014 
0.32 
μ 
0.017 
0.32
μ 
0.010 
Uniformity of 
Content 
(% w/w) b 
98.23 
μ 
0.18 
98.71 
μ 
0.29 
97.08
μ 
0.09 
98.62
μ 
0.07 
97.66
μ 
0.15 
98.25
μ 
0.08 
99.04 
μ 
0.23 
97.37 
μ 
0.07 
98.02
μ 
0.18 
Uniformity of 
Weight (mg) b 
161.8 
μ 
3.27 
159.7 
μ 
2.46 
162.0
μ 
3.05 
161.4
μ 
2.11 
160.9
μ 
1.28 
158.8
μ 
2.51 
159.3 
μ 
2.33 
161.3 
μ 
1.95 
161.5
μ 
2.83 
    a: mean μ SD, n= 6 ; b: mean μ SD, n=20 
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In-vitro drug release study 
The in vitro drug release data of HEP matrix tablets containing 
famotidine is presented in Table ă 4 and the drug release profiles is 
shown in Figure 3. Clearly identifiable differences were observed in 
the release behaviour of all famotidine formulations. In the 
formulations, release of famotidine in the first hour varies between 
49.69 in MT1 and 27.31 in MT9 and duration of drug release 
extended from 8 hour in MT1 to more than 12 hour in MT9 in the 
matrix tablet. The result reveals the effect of polymer concentration 
on release of famotidine from the HEP matrix tablet. With increase 
concentration of HEP retardation in drug release takes place, 
which clearly indicate the release rate controlling behaviour of 
HEP.  
When matrices containing swellable polymers are exposed to 
dissolution medium, tablet surface becomes wet and hydrated to 
form a gel layer. The initial release of drug from these matrices 
occurs by the drug dissolution in the water penetrated into the 
matrix. The overall drug release from these matrices is governed 
by hydration, gel layer formation and drug diffusion into gel layer 
and to the dissolution media [36]. As the concentration of HEP, it 
causes an increase in viscosity of the swollen gel matrix, which 
decreases the water diffusion in to the core layer. Decrease in 
hydration of matrix contributes more hindrance for drug diffusion 
and consequently decrease in release rate [37]. Polymer erosion 
also plays a major role in releasing drug from these matrices [38]. 
These considerations indicate that HEP have the potential to 
sustain the release of the drug from matrix tablets. 
 
 Table ă 4: Cumulative in-vitro drug release data of all batches. 
Time 
(Hrs) 
Cumulative % drug release
MT 1 MT 2 MT 3 MT 4 MT 5 MT 6 MT 7 MT 8 MT 9
0.5 
38.81 
μ 
1. 68 
36.09 
μ 
1.65 
34.74
μ 
1.98 
26.61
μ 
1.56 
23.17
μ 
1.86 
22.16
μ 
1.67 
17.29
μ 
1.89 
16.73 
μ 
1.96 
15.86
μ 
1.89 
1 
49.96 
μ 
1.72 
47.06 
μ 
1.45 
41.65
μ 
1.76 
38.15
μ 
1.67 
36.61
μ 
1.78 
33.76
μ 
1.79 
29.14
μ 
1.85 
27.48 
μ 
2.01 
27.31
μ 
1.87 
2 
58.82 
μ 
1.39 
56.17 
μ 
1.86 
51.07
μ 
1.64 
49.85
μ 
1.86 
47.04
μ 
1.53 
42.87
μ 
1.78 
38.07
μ 
1.73 
35.05 
μ 
2.21 
35.62
μ 
1.67 
3 
69.15 
μ 
1.51 
67.33 
μ 
2.23 
59.39
μ 
1.76 
58.54
μ 
1.75 
57.02
μ 
1.58 
52.41
μ 
1.79 
48.72
μ 
1.85 
44.50 
μ 
1.56 
44.07
μ 
1.62 
4 
78.37 
μ 
1.74 
74.92 
μ 
1.76 
68.94
μ 
1.54 
69.22
μ 
1.53 
68.29
μ 
1.75 
65.31
μ 
1.79 
59.73
μ 
1.93 
56.71 
μ 
1.84 
56.49
μ 
1.63 
5 
85.23 
μ 
1.89 
84.01 
μ 
1.87 
79.59
μ 
1.96 
78.31
μ 
1.68 
75.13
μ 
1.86 
72.89
μ 
1.94 
66.37
μ 
1.84 
62.36 
μ 
1.67 
62.33
μ 
1.89 
6 
95.03 
μ 
1.95 
91.22 
μ 
1.54 
88.61
μ 
1.65 
86.94
μ 
1.68 
81.72
μ 
1.56 
79.65
μ 
1.94 
74.52
μ 
1.93 
70.15 
μ 
1.73 
70.30
μ 
1.85 
8 
99.33 
μ 
1.54 
96.04 
μ 
1.52 
94.96
μ 
1.73 
93.73
μ 
1.59 
93.41
μ 
1.95 
88.50
μ 
1.78 
82.38
μ 
1.76 
78.84 
μ 
1.68 
78.63
μ 
1.84 
10  
99.87 
μ 
1.65 
99.27
μ 
1.78 
99.18
μ 
1.89 
99.82
μ 
1.79 
92.57
μ 
1.63 
89.02
μ 
1.74 
88.27 
μ 
1.69 
89.25
μ 
1.67 
12      
95.84
μ 
1.87 
94.33
μ 
1.69 
92.42 
μ 
1.89 
99.10
μ 
1.95 
14      
99.60
μ 
1.69 
99.94
μ 
1.57 
99.98 
μ 
1.23 
 
 
Deb et al. International Journal of Drug Delivery 6 (3) 311-325 [2014] 
 
 
  
PAGE | 318 |
 
 
Figure ă 3: In-vitro drug release profile for mucoadhesive Famotidine tablets 
 
Kinetic study of drug release 
The mechanism of drug release from matrix type drug delivery 
systems is a complex phenomenon. The R2 values and model 
constants of corresponding mathematical models are presented in 
Table ă 5. From the zero order and first order plots, it can be easily 
understood that increase in polymer concentration results in 
retardation of drug release. The best linearity was observed with 
Higuchi equation, indication drug release by diffusion through 
swellable matrix. A high linearity of Hixson cube-root model also 
been observed. Therefore it may be stated that, drug release from 
HEP matrix tablets follows diffusion coupled with erosion. The ÂnÊ 
value of Korsemeyer-Peppas model indicated the magnitude of 
drug diffusion from swellable matrix. The ÂnÊ values of the prepared 
formulations were found to be between 0.347 and 0.562. This 
implies that release may be fickian or non fickian (anamolous) 
depending upon polymer concentration. Higher concentration of 
natural polymer shifts the release pattern from fickian to non 
fickian. This indicates that at low polymer concentration only 
diffusion is dominating mechanism of release shifting to 
combination of diffusion and erosion based drug release 
mechanism when polymer concentration is increased.
 
Table ă 5: Kinetic analysis of in-vitro drug release mechanism. 
Model 
Formulation Code
MT 1 MT 2 MT 3 MT 4 MT 5 MT 6 MT 7 MT 8 MT 9
Zero Order 
Rñ 0.449 0.346 0.504 0.607 0.676 0.511 0.659 0.751 0.801
K₀ 16.096 13.373 12.917 12.766 12.529 9.356 9.001 9.571 9.790 
First Order 
Rñ 0.935 0.980 0.967 0.982 0.972 0.997 0.993 0.993 0.985
K₁ -0.1802 -0.1629 -0.1485 -0.1411 -0.1503 -0.1119 -0.0977 -0.0897 -0.0891 
Higuchi 
Rñ 0.977 0.937 0.966 0.986 0.995 0.969 0.990 0.994 0.993
KH 35.991 35.879 34.347 33.775 32.985 29.576 28.171 27.283 27.917 
Hixon-
Crowel 
Rñ 0.974 0.982 0.985 0.990 0.973 0.985 0.962 0.991 0.964
KHC -0.4239 -0.3691 -0.3430 -0.3415 -0.3606 -0.2524 -0.2548 -0.2159 -0.2646
Korsemayer 
- Peppas 
Rñ 0.988 0.992 0.980 0.994 0.993 0.984 0.988 0.992 0.993
KKP 48.176 46.463 41.220 37.709 34.968 35.075 29.854 27.004 25.468
n 0.347 0.352 0.375 0.448 0.482 0.459 0.521 0.534 0.562
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Statistical optimization of mucoadhesive tablets 
 In order to optimize the formulation of mucoadhesive tablet of 
famotidine, the effect of selected variables viz. amount of HEP and 
amount of PVP K30 was studied on the nature and the 
performance of the drug delivery device. The most influential 
responses those represent the nature and the overall performance 
of the formulated device are mucoadhesive strength (R1), 
mucoadhesion time (R2) and dissolution half-life (R3). According to 
the central composite design, nine formulations were prepared by 
varying the amount of independent variables. The individual and 
interactive effects of the independent variables on the selected 
responses have been studied and presented in a tabular form in 
Table ă 6. The data obtained in the study was statistically fitted to 
linear, interactive and quadratic models. 
 
 Table ă 6: Response parameters of various formulations prepared as per the experimental design. 
Formulation 
code 
Factor 1 Factor 2 Response B1 Response B2 Response B3 
HEP PVP K30 Mucoadhesion 
Strength 
Mucoadhesion Time T50 
% w/w % w/w N Min Min 
MT 1 20 (-1) 5 (-1) 11.1 μ 0.59 74 μ 1.89 99.6 μ 3.32
MT 2 20 (-1) 7.5 (0) 11.4 μ 0.78 73 μ 2.54 109.8 μ 3.86
MT 3 20 (-1) 10 (+1) 12.1 μ 0.65 76 μ 1.87 131.4 μ 2.89
MT 4 30 (0) 5 (-1) 41.8 μ 0.79 157 μ 2.13 138.0 μ 2.96
MT 5 30 (0) 7.5 (0) 42.1 μ 1.03 180 μ 1.76 148.8 μ 3.54
MT 6 30 (0) 10 (+1) 43.1 μ 1.12 196 μ 1.85 166.2 μ 3.21
MT 7 40 (+1) 5 (-1) 58.5 μ 0.98 381 μ 1.74 196.2 μ 2.95
MT 8 40 (+1) 7.5 (0) 59.9 μ 1.16 497 μ 1.98 216.6 μ 2.76
MT 9 40 (+1) 10 (+1) 52.9 μ 1.03 472 μ 2.13 213.6 μ 3.31
 
Statistical Data Analysis 
 The statistical analysis of the data obtained from trial batches was 
performed by multiple linear regression analysis using Design 
Expert® 8.0.7 software (Stat-Ease Inc. USA). The data clearly 
indicates that the values of three dependent variable viz. 
mucoadhesion strength, mucoadhesion time and dissolution half-
life strongly depends on independent variables viz. amount of HEP 
and PVP K30. Table 6 shows the results of analysis of variance 
(ANOVA), which was performed to identify significant and 
insignificant factors. The model F-values for the responses i.e. 
mucoadhesive strength, mucoadhesive time and T50 were found to 
be 147.81, 63.53 and 113.88 respectively. This implies that the 
models were significant. The values of prob > F (Less than 0.05) 
for all the responses indicated the significance of the model.The 
polynomial equations relating the responses to the factors have 
been generated by multiple linear regression analysis as 
expressed below (eq. 9-11) ă 
Mucoadhesion strength = 43.14 + 22.78X1 ă 0.55X2ă 1.65X1X2 
     ă 8.02X12 ă 1.22X22⁄⁄⁄...⁄. Eq. 9 
 
Mucoadhesion time = 193.67 + 187.83X1 + 22.00X2 + 22.25X1X2 
    + 84.50X12 ă 24.00X22 ⁄⁄⁄... Eq. 10 
 
Dissolution half-life (T50) = 157.80 + 47.60X1 + 12.19X2 .⁄ Eq. 11 
 
Where, X1 and X2 are coded values of the test variables i.e. 
amount of HEP and PVP K30 in %w/w. The equations can be used 
to draw the conclusion after considering the magnitude of the 
coefficient and the mathematical sign it carries. 
Effect on Mucoadhesive strength 
The polynomial equation for mucoadhesive strength (Eq. 9) 
indicates the positive effect of HEP and negative effect of PVP K30 
on mucoadhesion strength. As observed in the experimental set 
up, the mucoadhesion strength increased from 11.1 to 58.5 and 
from 12.1 to 52.9 at low and high level of PVP K30 respectively, as 
the concentration of HEP was increased, which clearly point 
towards the mucoadhesive potential of HEP. Whereas influence of 
PVP K30 is negligible as compare to natural polysaccharide (HEP). 
It is also observed that, at higher level, PVP K30 adversely affect 
the bioadhesion potential of the isolated polysaccharide. This is 
may be due to impaired swelling of the natural polysaccharide 
(HEP) matrix owing to polymeric interaction. Figure 4A and Figure 
4B represents the contour plot and 3D response surface plot 
clearly shows the influence of each polymer on the mucoadhesive 
strength of formulated tablets. From the plots a sharp 
augmentation of mucoadhesion is observed with increase in HEP 
concentration from 20% w/w to 30% w/w, this may be due to 
availability of more adhesive sites and polymer chains for 
interpenetration with the mucin as discussed earlier. 
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Figure ă 4A: Contour plot showing the influence of HEP and PVP K30 on the mucoadhesion strength. 
 
 Figure ă 4B: 3D Response Surface graph showing the influence of HEP and PVP K30 on the mucoadhesion strength. 
Effects on Mucoadhesion time 
The contour and response surface plot (Figure 5A and Figure 5B) 
illustrate that the value of mucoadhesion time increased from 
74minto 381min and from 76min to 472min at low and high level of 
PVP K30 respectively, as the concentration of HEP was increased 
while the value of mucoadhesion time increased from 74min to 
76min and from 381min to 472min at low and high levels of HEP 
respectively, as the concentration of PVP K30 was increased. 
Polynomial equation for mucoadhesion time (Eq. 10) illustrated that 
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both the independent variables viz. HEP and PVP K30 have 
additive effect on mucoadhesion time. It is also clear that the 
natural polysaccharide has a greater influence in the response 
variable as compare to PVP K30. 
 
 
Figure ă 5A: Contour plot showing the influence of HEP and PVP K30 on the mucoadhesion time. 
 
 
Figure ă 5B: 3D Surface Response graph showing the influence of HEP and PVP K30 on the mucoadhesion time. 
 
Effect on Dissolution half-life (T50) 
The polynomial equation for mucoadhesion time (Eq. 11) illustrates 
that both the variables viz. HEP and PVP K30 was found to have 
additive effect on T50. Figure 6A and Figure 6B represent the 
contour plot and three dimensional analysis for the studied 
response properties of time to 50% of famotidine release. From the 
contour plot it can be concluded that the T50 increases with 
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augmentation of both variables. The response changes the 
variables in a linear and ascending manner. But the contour plot 
shows that HEP has a completely greater influence on the 
response variables than the PVP K30. From the contour plot it is 
evident that the inclining trend was obtained with ascending order 
of HEP. The enhancement of T50 with increase in natural polymer 
concentration may be ascribed to increase in polymer chain density 
leading to pronounced chain entanglements and/or 
interpenetrations, thereby hindering the transport of drug molecules 
through the matrix. These findings point towards release retardant 
potential of HEP in formulation of matrix tablets. 
 
 
   Figure ă 6A: Contour plot showing the influence of HEP and PVP K30 on the dissolution half-life (T50). 
 
 Figure ă 6B: 3D Surface Response graph showing the influence of HEP and PVP K30 on the dissolution half-life (T50). 
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Search for optimum formulation 
This was the most important part of response surface 
methodology. Response surface optimization is more 
advantageous than the traditional single parameter optimization in 
that it saves time, space and raw material [39].  A numerical 
optimization technique using the desirability approach was 
employed to develop a new formulation with the desired 
responses. Upon comprehensive evaluation of the feasibility 
search and subsequently exhaustive grid searches, the formulation 
composition with HEP concentration of 40% and the amount of 
PVP K 30 was 9.63%, fulfilled maximum requirements of an 
optimum formulation, desirability 0.958. The higher desirability 
value indicates the more suitability of the formulation in terms of 
maximized mucoadhesion and better regulation of drug release 
rate. The optimized formulation was evaluated for various 
dependent variables. The response values were calculated and 
compared to the corresponding predicted values. Table 7 lists the 
values of the observed responses and those predicted by 
mathematical models along with the percentage prediction errors. 
The prediction error for the response parameters ranged between 
1.43 and 5.14%. 
 
Table ă 7: Comparison of experimentally observed responses of the optimized HEP mucoadhesive matrix tablet with predicted responses. 
Response parameter Observed value Predicted value Error (%) 
Mucoadhesive Strength (N) 52.325 55.161 5.14 
Mucoadhesive time (min) 479.194 486.166 1.43 
Dissolution half-life T50 (Min) 208.543 216.583 3.17 
 
Physical stability study 
Statistical analysis of the results, before and after conducting the 
stability studies for 3 months, was carried out using paired 
StudentÊs t-test. No significant difference (p > 0.05) was observed 
in the tablet appearance, hardness or thickness. The similarity 
factor (”2) was calculated for comparison of dissolution profile 
before and after stability studies. The ”2 values were found more 
than 50 (96.46 and 88.02 respectively after one and three months) 
that indicate a good similarity between both the dissolution profiles. 
Similarly, no significant difference was observed in the drug 
content, swelling percent, mucoadhesion strength and 
mucoadhesion time. The periodic data of stability study is 
presented in Table 8. The results of stability studies indicate that 
the developed formulation has good stability. 
 
Table ă 8: Results of short term physical stability study. 
Parameters 
Study period (Months) 
0 1 3 
Appearance Off-white coloured 
round shaped tablets 
Off-white coloured 
round shaped tablets 
Off-white coloured 
round shaped tablets 
Hardness (Kg/m2) 5.5 μ 0.07 5.6 μ 0.04 5.6 μ 0.08
Thickness (mm) 2.73 μ 0.02 2.73 μ 0.02 2.73 μ 0.01
Drug content (% w/w) 98.62 μ 0.17 98.74 μ 0.23 98.58 μ 0.13
Dissolution profile similarity factor (f2 %) 97 94 96 
Mucoadhesion strength (N) 53.72 μ 0.19 52.16 μ 0.26 52.85 μ 0.22
Mucoadhesion time (Minutes) 471 μ 3.83 494 μ 5.04 483 μ 3.29
 
Conclusion 
The experimental findings of the present study clearly pointed 
towards concentration dependant mucoadhesion and release 
retardant potential of purified Hibiscus esculentus L polysaccharide 
in the formulation of mucoadhesive matrix tablet of famotidine. 
Kinetic analysis reveals that the drug release from the formulation 
governs by chiefly diffusion coupled with surface erosion. A high 
degree of prognosis observed in the response surface analysis 
indicates efficiency and fitness of the selected model in 
optimization of formulation. The dependant variables, namely 
mucoadhesive strength, mucoadhesion time and dissolution half-
life found to be modulated by formulation variables viz. 
concentration of HEP and concentration of PVP K30. Though, the 
effect of HEP is much prominent as compare to that of PVP K30. 
This result indicates that, the purified polysaccharide of Hibiscus 
esculentus can be optimistically explored for potential 
mucoadhesive release retardant in various pharmaceutical 
formulations. 
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